What Is MeRT Therapy? Uses, Evidence, and Side Effects

MeRT, or Magnetic EEG-Guided Resonance Therapy, is a personalized form of transcranial magnetic stimulation (TMS) that uses a patient’s own brainwave recording to set the frequency of treatment, rather than relying on a one-size-fits-all protocol. It is marketed primarily for conditions like PTSD, depression, autism spectrum disorder, traumatic brain injury, and cognitive decline. Early clinical results, particularly for PTSD, look promising on paper, but the research base is still small, and important questions remain about whether the personalization actually improves outcomes beyond what standard TMS already offers.

How MeRT Works and What Makes It Different from Standard TMS

Standard repetitive TMS (rTMS) has been FDA-cleared for major depression and obsessive-compulsive disorder for years. It works by delivering magnetic pulses to specific brain regions, typically at a fixed frequency. The most common depression protocol, for instance, targets the left prefrontal cortex at 10 Hz. The parameters are largely the same from patient to patient.

MeRT changes the frequency piece. Before treatment begins, a clinician records a quantitative electroencephalogram (qEEG) to measure the patient’s individual brainwave activity, specifically their alpha rhythm, which falls somewhere in the 8 to 13 Hz range. An algorithm then determines the patient’s dominant alpha frequency, and the TMS device is set to deliver pulses at that specific rate. The idea is that PTSD, traumatic brain injury, and other neurological conditions are associated with weakened or disorganized alpha-band activity, and stimulating at the brain’s own natural frequency might restore healthier patterns more effectively than a generic setting would.¹

Throughout a treatment course, the qEEG is typically repeated at intervals so clinicians can adjust the stimulation parameters as the brain’s activity changes. Proponents argue this makes MeRT an adaptive therapy rather than a static one. In practice, the treatment session itself looks almost identical to standard rTMS from the patient’s perspective: you sit in a chair, a coil is placed against your head, and you feel rapid tapping sensations for about 30 to 45 minutes.

Evidence for PTSD

PTSD is the condition with the most MeRT-specific data so far, though “most” is relative. The studies are small. One study of MeRT in PTSD patients found that after treatment, roughly two-thirds met the standard response threshold on the PCL-5 (a widely used PTSD symptom checklist), and about four in five showed what researchers considered clinically meaningful improvement.¹ Those numbers sound impressive, but the study was not large, and the strength of any conclusion scales with sample size.

A separate retrospective review looked at military servicemembers who participated in an individually guided alpha-frequency rTMS program. Over four weeks, average depression scores dropped by roughly half, and concussion-related symptom scores fell by close to half as well.² Those are meaningful drops, but retrospective chart reviews are among the weaker study designs because there is no control group and no blinding. It is impossible to separate the treatment effect from placebo response, natural recovery over time, or other therapies the patients may have been receiving simultaneously.

Broader reviews of TMS for PTSD, not MeRT specifically, have found that high-frequency stimulation tends to show better results on PTSD rating scales than low-frequency stimulation. But overall, results across studies have been inconsistent, and sample sizes remain small.³ The picture is one of an approach that is plausibly helpful but not yet proven in the way large randomized trials can prove something.

Evidence for Depression

Depression often accompanies PTSD, so many MeRT studies report depression scores alongside PTSD scores rather than studying depression on its own. In the PTSD study mentioned above, patients who had at least moderate depression symptoms at baseline saw some improvement: just under half met the standard response threshold on the PHQ-9 depression questionnaire, and about two-thirds showed clinically meaningful change.¹

These results are encouraging but come with a caveat that cuts to the heart of MeRT’s selling point. Among patients who had previously received standard (non-personalized) TMS, the depression response rates were identical between MeRT and their prior TMS treatment.¹ That subgroup was tiny, only five people, so it would be wrong to draw firm conclusions from it. But it raises the question researchers and patients both need answered: does tuning the frequency to your individual alpha rhythm actually improve outcomes, or does the benefit come from TMS itself regardless of the exact parameters?

Autism Spectrum Disorder

MeRT clinics frequently list autism spectrum disorder as a target condition. The available research here is mostly on TMS broadly rather than the MeRT-specific protocol, and it paints a mixed picture. A systematic review and meta-analysis of TMS for autism found moderate effects on repetitive and stereotyped behaviors, social behavior, and certain executive function tasks. Other outcomes did not reach statistical significance.⁴

The review flagged significant quality problems in the studies it analyzed. Most had a moderate to high risk of bias, largely because participants and evaluators knew who was getting real treatment and who was getting sham. Only five studies tracked whether improvements lasted, and those that did reported gains holding for up to six months. The review’s bottom line was that TMS could be useful for some dimensions of autism but that the evidence needed to be treated carefully given the lack of adequate placebo controls.⁴

Researchers are working to fill these gaps. A protocol for a double-blind, sham-controlled randomized trial of rTMS in children and adolescents with autism uses low-frequency stimulation at 90% of the motor threshold to minimize seizure risk while still potentially modulating cortical activity.⁵ Trials like this, with proper blinding and sham controls, are what the field needs before anyone can say with confidence that TMS, let alone the personalized MeRT version, reliably benefits autistic individuals.

Side Effects and Safety Profile

Because MeRT uses the same underlying technology as standard rTMS, its side effect profile is similar and, for the most part, mild. The most commonly reported issues include:

Headaches: reported by roughly 30% of patients, usually mild and manageable with over-the-counter pain relievers.
Facial muscle twitching: also around 30%, caused by the magnetic field activating muscles near the coil.
Lightheadedness or dizziness: about 20%, typically brief and resolving with rest after the session.
Discomfort at the stimulation site: about 20%, a sensation of pressure or mild pain where the coil sits.
Fatigue: less common, reported in roughly 1 to 7% of patients.⁶

The side effect most people worry about is seizure. It can happen, but the risk is very low, estimated at less than 0.1%.⁶ When seizures do occur during TMS, they are almost always linked to predisposing factors like a personal seizure history, certain medications that lower seizure threshold, or stimulation parameters that exceeded safety guidelines.³ Reputable clinics screen for these risk factors before starting treatment. In pediatric populations, protocols tend to use lower stimulation intensities as an added safety measure.⁵

Overall, the side effect picture for MeRT mirrors that of standard rTMS: uncomfortable at times, occasionally annoying, but rarely dangerous. Most side effects resolve during or shortly after treatment and do not require medical intervention beyond ibuprofen or acetaminophen.

Why the Evidence Deserves Careful Scrutiny

The research on MeRT is in its early stages, and nearly every study acknowledges the same core set of limitations. Sample sizes are small. Study durations are short, making it hard to know whether improvements last. And the challenge of creating a convincing placebo condition for brain stimulation has not been fully solved.⁷

That last point matters more than it might seem. Sham-controlled trials in TMS use a device that looks and sounds like the real thing but does not deliver a therapeutic pulse. But even sham coils can produce scalp sensations that differ subtly from active treatment, and patients can sometimes guess which group they are in. Researchers building randomized controlled trials for MeRT have tried to address this with double-blinding and sham coils, but they acknowledge these common problems in TMS research cannot be entirely eliminated.⁷ This is a persistent issue across the entire field of non-invasive brain stimulation, not something unique to MeRT.

The autism research faces an even steeper challenge. As the meta-analysis noted, most studies in that area did not adequately control for placebo effects, and the majority had moderate to high risk of bias.⁴ When you combine a plausible-sounding treatment with intensive clinical attention, a high-tech setting, and the hope that comes with trying something new, the placebo response can be substantial. Separating that from a genuine neurological effect requires rigorous trial design that much of the current evidence simply does not provide.

The Personalization Question

If you are considering MeRT specifically, rather than standard TMS, the question you should be asking is whether the EEG-guided personalization adds something beyond what conventional protocols already achieve. The honest answer right now is that nobody knows for certain. The theoretical rationale is appealing: PTSD and traumatic brain injury are associated with disrupted alpha-band activity, and stimulating at the brain’s own preferred alpha frequency should, in theory, be more effective at normalizing those patterns than a fixed generic frequency.¹

But theory and clinical proof are different things. The small head-to-head comparison from the PTSD study, where patients who had previously tried standard TMS showed identical depression response rates with MeRT, is not enough evidence to draw conclusions from, but it is enough to flag the question as genuinely unanswered.¹ Until large, properly controlled trials directly compare MeRT with standard TMS protocols in the same patient population, the premium that MeRT clinics charge for the personalized approach is based on a reasonable hypothesis rather than established proof of superiority.

What Treatment Typically Looks Like in Practice

A typical MeRT course begins with a qEEG recording session, during which you sit quietly with electrodes on your scalp for roughly 15 to 20 minutes while the system captures your brainwave data. The clinic then uses that data to determine your treatment parameters. Treatment itself usually runs five days per week for two to four weeks, with each session lasting about 30 to 45 minutes. Many providers repeat the qEEG at regular intervals, often weekly, and adjust the frequency or coil placement if the data suggests your brain’s patterns are shifting.

Cost is one of the biggest practical considerations. Standard TMS for depression is covered by most insurance plans in the United States because it has FDA clearance and a substantial evidence base. MeRT, by contrast, is typically offered through specialized clinics and is often not covered by insurance. Out-of-pocket costs can run several thousand dollars for a full treatment course. Some clinics offer financing or work with veterans’ organizations to subsidize treatment for military servicemembers, which is one reason why much of the early MeRT research has focused on active-duty and veteran populations.

If you are weighing MeRT against standard TMS, the practical differences beyond cost are mostly front-loaded. The qEEG adds an assessment step and introduces the possibility of treatment adjustments over time. The day-to-day experience of sitting through sessions is largely the same. Both approaches carry similar side effect profiles. The meaningful difference is in whether the EEG-guided frequency selection improves your individual outcome, and as discussed, the data on that specific question remain thin.

Conditions Where Evidence Is Even Thinner

Some MeRT providers list traumatic brain injury, concussion symptoms, sleep disorders, anxiety, and cognitive decline as conditions they treat. For most of these, the evidence supporting MeRT specifically is either preliminary or nonexistent in the peer-reviewed literature. The military servicemember study did track concussion-related symptoms and found meaningful score reductions, but that was a retrospective chart review with no control group.²

For cognitive decline, research into using qEEG biomarkers to predict who will respond to rTMS is still at the protocol stage, meaning researchers are designing the studies but have not yet published results.⁶ The gap between what clinics promote and what the published evidence supports is wider for these conditions than it is for PTSD or depression. That does not mean MeRT cannot help with concussion symptoms or cognitive decline. It means the science has not yet caught up to the marketing, and you should weigh that when making decisions about treatment and spending.

For any condition where the evidence base is this young, asking a provider to walk you through the specific studies supporting their claims, and whether those studies used sham controls and blinding, is a reasonable first step. A provider who is transparent about the limitations of the data is generally one worth trusting more than one who speaks only in success rates.

1
Transcranial Magnetic Stimulation. Magnetic EEG-Guided Resonance Therapy (MeRT) in PTSD
2
PubMed Central. A Retrospective Chart Review of PTSD Symptoms in Military Servicemembers Participating in an Individually Guided Neuromodulation (Alpha-rTMS) Wellness Program
3
PubMed Central. Transcranial Magnetic Stimulation for Post-traumatic Stress Disorder
4
PubMed Central. Repetitive Transcranial Magnetic Stimulation for Treatment of Autism Spectrum Disorder: A Systematic Review and Meta-Analysis
5
PubMed Central. Repetitive transcranial magnetic stimulation in children and adolescents with autism spectrum disorder
6
PubMed Central. Quantitative Electroencephalographic Biomarkers for Repetitive Transcranial Magnetic Stimulation Treatment Response Prediction in Mild Cognitive Impairment
7
Personalized Medicine in Psychiatry. Personalized electrophysiology-guided transcranial magnetic stimulation in post-traumatic stress disorder: a randomized, double-blind, sham-controlled study